Volume 11, 1996 Index

Author Index

Abbott, R, S36
Abram, HS, 276
Afifi, AK, 497
Ahdab-Barmada, M, 252
Aicardi, J, 439
Aktan, G, 373
Albright, AL, 77, 370, S1, S29
Al Deeb, SM, 241
Al Hifzi, I, 378
Alroy, J, 301
Al Shawan, SA, 241
Altman, N, 445
Alvarez, L, 445
Alvord, EC Jr, 313
Ames, C, 159
Andermann, E, 211
Anderson, AE, 215
Anderson, L, 476
Anhut, H, 470
Anlar, B, 458
Arenas, J, 108
Ater, JL, 462
Awaad, Y, 167
Aylward, EH, 112

Bakshi, N, 159
Bamboukas, M, 309
Baquis, GD, 407
Barnes, P, 164
Barry, MJ, S51
Bass, NE, 422
Battistella, PA, 414
Bauer, L, 121
Bawden, H, 41, 506
Baylen, BG, 49
Beggs, AH, 291
Beiras-Iglesias, A, 108
Bell, WE, 497
Bharucha, KJ, 353
Bigelow, TM, 101
Black, JB, 74
Black, K, 250
Bobele, GB, 246, 404
Bodensteiner, JB, 75, 236, 255, 347
Bohl, J, 265
Boltshauser, E, 210
Bonnet, KA, 483
Booth, MP, 321
Boulloche, J, 439
Bourgeois, M, 439
Braak, E, 265
Braak, H, 265
Breningstall, GN, 345
Brown, JE, 112
Brualla, J, 492
Brumback, RA, 220, 246, 263, 404, 427
Bruyn, GW, 241
Buonanno, F, 248
Burlina, AB, 414
Burns, DK, 476
Burt, AD, 417
Butler, IJ, 215

Camfield, C, 341
Camfield, P, 41, 341, 506
Campbell, SK, S61
Campos, Y, 108
Cantrell, DTC, 350
Cargan, AL, 336
Carmel, PW, 336
Cassidy, SB, 121
Castillo, R, 462
Castro-Gago, M, 108
Cavouras, D, 197
Chamberlain, MC, 31
Chapman, CA, 63
Chiba, S, 430
Chiriboga, CA, 336
Chudnow, R, 507
Chugani, DC, 451
Chugani, HT, 44, 167, 451
Cianchetti, C, 343
Cohen, B, 422
Conti, JR, 44
Cook, MA, 157
Copeland, DR, 462
Courchesne, E, 84
Coyne, CM, 101, 433
Cramer, SC, 494
Craver, RD, 185, 410
Crawford, SE, 58

Darling, CF, 58
Davidovitch, M, 389
Davis, DG, 101
Davis, R, 164
Dean, P, 445
de León, GA, 58
Delgado, MR, 1, 476
DeMontis, N, 343
Denckla, MB, 112
Denson, SE, 215
De Salles, AAF, S43
de Silva, RD, 157
De Vivo, DC, 336
DiMario, FJ Jr, 121
Diven, W, 252
Dooley, J, 341
Drigo, P, 414
Duane, DD, 505
Duchowny, M, 445
Duncan, MC, 185
du Plessis, A, 63

Eaton, DM, 70
Ebb, D, 248
Ebersole, J, 470
Eiben, RM, 126
Eirís-Puñal, J, 108
Elterman, RD, 259, 350
Engel, AG, 345
Erdem, G, 373
Ertan, M, 458

Feeback, DL, 246
Felice, KJ, 116
Fennell, EB, 321
Ferriero, DM, 25
Filiano, J, 54
Filloux, FM, S5
Fishman, MA, 331
Fletcher, JM, 283
Francis, DJ, 462
Freilinger, M, 201
Fugate, JH, 345

Gamstorp, I, 394
Gao, X-K, 483
Gardner-Medwin, D, 417
Garofalo, E, 470
Gartside, P, 389
Gates, AJ, 410
Giachnakis, M, 309
Gingold, M, 236
Glick, RS, 336
Goldstein, R, 445
Golfinopoulos, S, 197
Golladay, SE, 410
Good, WV, 25
Gordon, K, 41, 341, 506
Goto, Y, 71
Gottlieb, SM, 419
Gould, RJ, 250
Goutières, F, 439
Griffiths, PD, 417
Groh, C, 201
Guerina, N, 162
Gupta, S, 501
Gutierrez, A, 172

Haas, RH, 84
Hahn, JS, 490
Hansen, A, 162
Hanson, R, 159
Harper, CR, 220, 427
Harvey, AS, 445
Harward, H, 283
Haslam, R, 400, 489
Hauger, SB, 336
Hauser, E, 201
Henderson, M, 70
Hermann, R, 66
Hirano, S, 205
Hogg, JP, 236
Hoon, AH Jr, 261
Huggle, S, 433
Hunsaker, JC III, 101, 433
Hurst, DL, 170
Iannaccone, ST, 171, 350, 476
Idizabal, MA, 492
Inagaki, M, 205
Ioannidou, M, 197

Jackson, AH, 407
Jackson, LA, 93
Jacobs, C, 373
Jaffe, M, 98
Jay, V, 400, 489
Jayakar, P, 445
Jaynes, M, 172
Johnson, GS, 58
Jones, HR Jr, 4, 116
Joseph, SA, 422
Jouppila, P, 189

Kaga, M, 205
Kandt, RS, 347
Kaufman, HH, 236
Kaye, EM, 301
Kerrin, D, 70
Keskin, S, 235
Khan, M, 378
Khandji, AG, 336
Khurana, DS, 248
Kikuchi, K, 430
Kinoshita, H, 205
Kirkinen, P, 189
Knepper, LE, 276
Koman LA, S23
Korson, M, 54, 162
Kotagal, S, 507
Koukkari, MW, 490
Kozuka, N, 430
Krishnamoorthy, KS, 248, 494
Kurachek, SC, 345
Kusnerik, L, 283

Lachar, D, 283
LaMoreaux, L, 470
Landers, TM, 101
Landry, SH, 215
Lappalainen, R, 296
La Russa, PS, 336
Lawson, J, 159
Leach, RJ, 211
Leech, RW, 246, 259, 263, 404, 507, 508
Legarda, SB, 321
Lerman-Sagie, T, 54, 162
Levin, B, 445
Levin, HS, 283
Lewis, TB, 211
Lichter, DG, 93
Lilly, MA, 283
Lincoln, AJ, 84
Lindholm, D, 296
Liu, H, 101
Livingston, J, 70

Volume 11, 1996 Index

Author Index

Abbott, R, S36
Abram, HS, 276
Afifi, AK, 497
Ahdab-Barmada, M, 252
Aicardi, J, 439
Aktan, G, 373
Albright, AL, 77, 370, S1, S29
Al Deeb, SM, 241
Al Hifzi, I, 378
Alroy, J, 301
Al Shawan, SA, 241
Altman, N, 445
Alvarez, L, 445
Alvord, EC Jr, 313
Ames, C, 159
Andermann, E, 211
Anderson, AE, 215
Anderson, L, 476
Anhut, H, 470
Anlar, B, 458
Arenas, J, 108
Ater, JL, 462
Awaad, Y, 167
Aylward, EH, 112

Bakshi, N, 159
Bamboukas, M, 309
Baquis, GD, 407
Barnes, P, 164
Barry, MJ, S51
Bass, NE, 422
Battistella, PA, 414
Bauer, L, 121
Bawden, H, 41, 506
Baylen, BG, 49
Beggs, AH, 291
Beiras-Iglesias, A, 108
Bell, WE, 497
Bharucha, KJ, 353
Bigelow, TM, 101
Black, JB, 74
Black, K, 250
Bobele, GB, 246, 404
Bodensteiner, JB, 75, 236, 255, 347
Bohl, J, 265
Boltshauser, E, 210
Bonnet, KA, 483
Booth, MP, 321
Boulloche, J, 439
Bourgeois, M, 439
Braak, E, 265
Braak, H, 265
Breningstall, GN, 345
Brown, JE, 112
Brualla, J, 492
Brumback, RA, 220, 246, 263, 404, 427
Bruyn, GW, 241
Buonanno, F, 248
Burlina, AB, 414
Burns, DK, 476
Burt, AD, 417
Butler, IJ, 215

Camfield, C, 341
Camfield, P, 41, 341, 506
Campbell, SK, S61
Campos, Y, 108
Cantrell, DTC, 350
Cargan, AL, 336
Carmel, PW, 336
Cassidy, SB, 121
Castillo, R, 462
Castro-Gago, M, 108
Cavouras, D, 197
Chamberlain, MC, 31
Chapman, CA, 63
Chiba, S, 430
Chiriboga, CA, 336
Chudnow, R, 507
Chugani, DC, 451
Chugani, HT, 44, 167, 451
Cianchetti, C, 343
Cohen, B, 422
Conti, JR, 44
Cook, MA, 157
Copeland, DR, 462
Courchesne, E, 84
Coyne, CM, 101, 433
Cramer, SC, 494
Craver, RD, 185, 410
Crawford, SE, 58

Darling, CF, 58
Davidovitch, M, 389
Davis, DG, 101
Davis, R, 164
Dean, P, 445
de León, GA, 58
Delgado, MR, 1, 476
DeMontis, N, 343
Denckla, MB, 112
Denson, SE, 215
De Salles, AAF, S43
de Silva, RD, 157
De Vivo, DC, 336
DiMario, FJ Jr, 121
Diven, W, 252
Dooley, J, 341
Drigo, P, 414
Duane, DD, 505
Duchowny, M, 445
Duncan, MC, 185
du Plessis, A, 63

Eaton, DM, 70
Ebb, D, 248
Ebersole, J, 470
Eiben, RM, 126
Eirís-Puñal, J, 108
Elterman, RD, 259, 350
Engel, AG, 345
Erdem, G, 373
Ertan, M, 458

Feeback, DL, 246
Felice, KJ, 116
Fennell, EB, 321
Ferriero, DM, 25
Filiano, J, 54
Filloux, FM, S5
Fishman, MA, 331
Fletcher, JM, 283
Francis, DJ, 462
Freilinger, M, 201
Fugate, JH, 345

Gamstorp, I, 394
Gao, X-K, 483
Gardner-Medwin, D, 417
Garofalo, E, 470
Gartside, P, 389
Gates, AJ, 410
Giachnakis, M, 309
Gingold, M, 236
Glick, RS, 336
Goldstein, R, 445
Golfinopoulos, S, 197
Golladay, SE, 410
Good, WV, 25
Gordon, K, 41, 341, 506
Goto, Y, 71
Gottlieb, SM, 419
Gould, RJ, 250
Goutières, F, 439
Griffiths, PD, 417
Groh, C, 201
Guerina, N, 162
Gupta, S, 501
Gutierrez, A, 172

Haas, RH, 84
Hahn, JS, 490
Hansen, A, 162
Hanson, R, 159
Harper, CR, 220, 427
Harvey, AS, 445
Harward, H, 283
Haslam, R, 400, 489
Hauger, SB, 336
Hauser, E, 201
Henderson, M, 70
Hermann, R, 66
Hirano, S, 205
Hogg, JP, 236
Hoon, AH Jr, 261
Huggle, S, 433
Hunsaker, JC III, 101, 433
Hurst, DL, 170
Iannaccone, ST, 171, 350, 476
Idizabal, MA, 492
Inagaki, M, 205
Ioannidou, M, 197

Jackson, AH, 407
Jackson, LA, 93
Jacobs, C, 373
Jaffe, M, 98
Jay, V, 400, 489
Jayakar, P, 445
Jaynes, M, 172
Johnson, GS, 58
Jones, HR Jr, 4, 116
Joseph, SA, 422
Jouppila, P, 189

Kaga, M, 205
Kandt, RS, 347
Kaufman, HH, 236
Kaye, EM, 301
Kerrin, D, 70
Keskin, S, 235
Khan, M, 378
Khandji, AG, 336
Khurana, DS, 248
Kikuchi, K, 430
Kinoshita, H, 205
Kirkinen, P, 189
Knepper, LE, 276
Koman LA, S23
Korson, M, 54, 162
Kotagal, S, 507
Koukkari, MW, 490
Kozuka, N, 430
Krishnamoorthy, KS, 248, 494
Kurachek, SC, 345
Kusnerik, L, 283

Lachar, D, 283
LaMoreaux, L, 470
Landers, TM, 101
Landry, SH, 215
Lappalainen, R, 296
La Russa, PS, 336
Lawson, J, 159
Leach, RJ, 211
Leech, RW, 246, 259, 263, 404, 507, 508
Legarda, SB, 321
Lerman-Sagie, T, 54, 162
Levin, B, 445
Levin, HS, 283
Lewis, TB, 211
Lichter, DG, 93
Lilly, MA, 283
Lincoln, AJ, 84
Lindholm, D, 296
Liu, H, 101
Livingston, J, 70

Lorente, S, 155
Lowichik, A, 258

Maegaki, Y, 205
Majeed-Saidan, M, 378
Malashkhia, VY, 500
Malashkhia, YA, 500
Mann, S, 41, 506
Maria, BL, 321
Maroto, S, 108
Marrosu, MG, 343
Martikainen, A, 189
Mason, TBA III, 336
Mathews, KD, 193
Méhes, K, 66
Mendel, RC, 404
Mendelsohn, D, 283
Menezes, AH, 497
Micheloyannis, S, 309
Miller, CL, 215
Miller, G, 49
Miller, PD, 370
Molinari, L, 309
Mooney, JF III, S23
Moore, BD III, 462
Morris, AAM, 417
Murray, N, 181
Myer, EC, 244
Myers, JL, 49
Myers, S, 470

Nadareishvili, ZG, 500
Nakagawa, E, 71
Narayanan, V, 252
Nelson, JS, 185, 410
Nester, MJ, 173
Newton, CRJC, 257
Nonaka, I, 71
North, KN, 291

Ohya, K, 430
Orlik, P, 41, 506
Ouvrier, R, 133
Ozawa, M, 71
Özdirim, E, 458

Painter, MJ, 276
Pamphlett, R, 181
Pang, D, 370
Paritsis, N, 309
Partridge, JC, 25
Patterson, B, 389
Pavlakis, SG, 250
Perry, RH, 417
Pintor, M, 343
Pintos-Martínez, E, 108
Piovan, S, 414
Pober, BR, 63
Pollack, IF, 370
Pollay, M, 404
Pranzatelli, MR, S13, 355
Prasad, A, 301
Prassopoulos, P, 197
Prokopakis, M, 309
Puppa, AD, 414

Quinlan, JG, 13, 21

Raguthu, S, 157
Ramer, JC, 49
Rapin, I, 348
Rasheed, K, 101
Reader, MJ, 112
Reed, LA, 497
Reiss, AL, 112
Renda, Y, 373
Resnick, T, 445
Riela, AR, 425, 509
Riggs, JE, 255
Riikonen, RS, 296, 383
Rimland, B, 501
Riviello, JJ Jr, 164
Roach, ES, 425, 476
Rolak, LA, 461
Rosman, NP, 419
Ruff, A, 258
Ryan, SG, 211
Ryynänen, M, 189

Saatçi, I, 373
Samaha, FJ, 13, 21
Schaefer, PW, 494
Schochet, SS, 236
Schraufnagel, CD, 220
Schreibman, L, 84
Schutgens, RBH, 373
Seidl, R, 201
Seki, T, 35
Serlo, W, 189
Sethi, RK, 291
Shah, BL, 407
Shamato, H, 167
Shamoto, H, 451
Shank, T, 236
Shapiro, F, 291
Shaw, C-M, 313
Sheth, RD, 255, 259, 347
Shevell, MI, 211
Shilling, PD, 501
Shramek, JK, 157
Sieratzki, JS, 347
Şimşek, A, 373
Singer, HS, 112
Singh, B, 378
Singh, P, 378
Singh-Kler, R, 417
Slopis, J, 462
Smith, BP, S23
Smith, DW, 54
Smith, KE, 215
Smith, M, 70
Sparks, DL, 101, 433
Specht, LA, 291
Stack, C, 58
Stafstrom, CE, 170
Steinberg, GK, 490
Stern, MJ, 157
Stich, RA, 419
Sugai, K, 71
Swank, PR, 215

Tachi, N, 430
Takuma, Y, 35
Tam, DA Jr, 244
Tesman, JR, 49
Thiele, E, 164
Tirosh, E, 98
Topçu, M, 373
Townsend, J, 84
Trudeau, V, 470
Tsay, CH, 25
Turnbull, DM, 417
Tzenaki, M, 309

Uclés, P, 155

Vajsar, J, 400, 489
Valdizán, JR, 492
Vanefsky, MA, 490
Varli, K, 458
Villarreal, SF, 25
Vinters, HV, 159
Volpe, J, 121

Wanders, RJA, 373
Warrier, RP, 410
Warty, VS, 276
Weinberg, WA, 220, 427
Weintraub, MI, 171
Wildin, SR, 215
Woll, B, 347
Wong, CP, 417
Woodside, M, 215
Wright, RR, 193
Wyllie, E, 422

Yamanouchi, H, 71
Yeakley, JW, 260
Yeung-Courchesne, R, 84
Yilmazer, D, 265
Yurdakul, F, 235

Zuddas, A, 343

Subject Index

Absence seizures, 470–474
Acetazolamide, 364
Acetylcholinesterase deficiency, 345–346
Acidemia, 373–377
Acid maltase, 148–149
Activator deficiency, 302
Acute intermittent porphyria, 229
ADHD, 93–96, 112–115, 155–156, 220–227
Adolescence, 220–227, S57
Adrenergic antagonists, 361–362
Adrenoleukodystrophy, 231, 497–499
Adrenoreceptor agonists, 361
Adult-onset acid maltase deficiency, 148
Adynamia episodica hereditaria, 395–396
Affective illness, 220–227
Agonists, 361, 362
Alcohol, S25
Alignment, postural, S67
Alpha adrenoreceptor agonists, 361
ALZ-50 immunoreactivity, 101–106
Amaurosis, 108–111
American Board of Psychiatry and Neurology, 479–482
Amitriptyline, 226, S15
Amygdala, 271–272
Amylaceous polyglucosan bodies, 58–62
Amyotrophic lateral sclerosis, 54–57, 152
Amyotrophy, 150
Andersen's syndrome, 151–152
Anesthetics, 363
Antagonists, 361–362
Antiadrenergics, S15
Anticholinergics, 362, S15
Anticoagulation, 248–249
Anticonvulsants, 244–245, 321–330, 363, 476, S15
Antidepressants, 226, 362, S15
Antidopaminergics, S15
Antidyskinetics, 355–366
Antiepileptics, 244–245, 321–330
Antiglutamatergics, 365
Antihistamines, 362, S15
Antimanics, 227
Antimicrobials, 366

Antioxidants, 365
Antiparkinsonian agents, S15
Antispasticity agents, S15
Aphasia, 347–349
Apnea, 98–100, 162–164
Apolipoproteins, 279
Apomorphine, 343–345
Apoptosis, 433
Areflexia, 252–254
Arrhythmia, 121–124
Arterial thrombosis, 250–251
Arteries, 181–184, 250–251, 494–496
Ashworth scale, S29
Asperger syndrome, 427–428, 483–487
Astrocytoma, 230, 462–468, 469
Astrogliosis, 433
Athetodystonia, S47
Athetosis, S2–S3, S14
Atrophy, 58–62, 153, 154, 246–247
Attention-deficit hyperactivity disorder, 93–96, 112–115, 155–156, 220–227
Auditory brainstem response, 205–209
Autism, 84–91, 389–392, 486, 501–503
Autonomic dysfunction, 162–164
Axonal neuropathy, 153–154, 400–403

Baclofen, 77–82, 167–169, 360, S15, S16, S29–S34
Balance, S68
Basal forebrain, 272
Basal ganglia, 112–115, 356–357, S8–S9, S18–S19, S48–S49
Basilar artery, 181–184
Becker muscular dystrophy, 14, 150
Behavioral outcomes, 283–289
Benign familial convulsions, 211–214
Benzodiazepines, S15
Benztropine, S15
Beta-adrenergic antagonists, 361–362
Bethlem myopathy, 147
Bilateral ptosis, 228–229
Bilateral striatal necrosis, 185–187
Birth weight, 215–219
Blink reflex, 205–209
Blood flow, 231
Blunt intraoral trauma, 419–422
Bone marrow transplantation, 159–161
Botulinum toxin, 231–232, 364, S25–S27
Brain, 38, 58–62, 160–161, 181–184, 228–229, 259, 272, 357, 507
Brief Assessment Examination, 173–180
Bupropion, 226

Calcium–channel blockers, 363
Camptomelic dysplasia, 228
Canadian Occupational Performance Measure, S63
Canavan disease, 373–377
Candida, 336–340
Carbamazepine, 227, 378–381, 476–478, S15, S16
Carbidopa, S15, S16
Cardiomyopathy, 17
Carnitine, 326–327
Carotid arteries, 181–184
Castleman's disease, 149
Casts, S53
Central apnea, 162–164
Central nervous system, 71–73, 496
Ceramidase activator deficiency, 302
Cerebellum, 357, 451–456
Cerebral artery, 250–251, 494–496
Cerebral atrophy, 58–62
Cerebral blood flow, 231
Cerebral circulation, 347
Cerebral cortex, 272–273
Cerebral dysgenesis, 228
Cerebral dysplasia, 313–320
Cerebral malaria, 257–258
Cerebral palsy, 49–52, 75–82, 205–209, S1–S3, S5–S11, S13–S20, S23–S34, S43–S49, S51–S58, S61–S68
Cerebral venous thrombosis, 248–249
Cerebrospinal fluid, 296–300, 384–385, 386
Cerebrovascular disorders, 508
Ceroid lipofuscinosis, 234, 302, 307
Charcot-Marie-Tooth disease, 133–144, 147
Chelators, 366
Chewing gum, 210
Child neurology, as independent discipline, 331–335
Chlorpromazine, S15
Cholesterol, 276–281
Chorea, 490–491, S3, S14
Choreoathetosis, 185–187, S14
Chronic inflammatory demyelinating polyneuropathy, 147, 149
Cingulate circuit, 271
Clomipramine, S15
Clonazepam, S15, S16
Clonidine, 93–96, 227, S15
Coagulopathy, 244–245
Cocaine, 25–30
Cognitive function, 321–330
Congenital amaurosis, 108–111
Congenital autonomic dysfunction, 162–164
Congenital endplate acetylcholinesterase deficiency, 345–346
Congenital fiber-type disproportion myopathy, 71–73
Congenital fumarase deficiency, 252–254
Congenital heart disease, 49–52
Congenital hemiplegia, S7–S8
Congenital muscular dystrophy, 291–295
Congenital myotonic dystrophy, 430–432
Congenital neuropathy, 139, 153
Contraceptives, 364
Convulsions, 211–214
Cortex, 272–273
Corticosteroids, 363
Corticotropin, 35–40
Cramps, 16–17, 21–23, 230
CTG repeat size, 430–432

Dandy-Walker malformation, 410–413
Dantrolene, 364, S15, S16
Deafness, 153
Dejerine-Sottas disease, 141–142
Demyelinating polyradiculoneuropathy, 147, 149
Desipramine, 226
Desminopathy, 149
Development disorder, 427–428
Dextro-amphetamine, 227
Diaminopyridine, 458–460
Diazepam, S15, S16
DiGeorge syndrome, 494–496
Dimethothiazine, S17
Diphenhydramine, S15
Diphenylhydantoin, S15
Disability, S61–S64
Dopamine, 361, S19
Dopaminergic drugs, 343–345, S15
Dopa-responsive dystonia, 353
Down syndrome, 66–69
Doxepin, 226
Duchenne muscular dystrophy, 13
Dysgenesis, 228
Dyskinesias, 355–366
Dysmyelinating neuropathy, 139
Dysplasia, 228, 313–320
Dyspraxia, 484
Dysrhythmia, 151–152
Dystonia, 185–187, 343–345, 353, 360, S2, S14, S31
Dystrophin, 13, 152–153
Dystrophinopathy, 13–18, 21–23, 149
Dystrophy, 13–18, 150, 154, 291–295, 430–432

EEG, 41–43, 309–312, 445–449, 485
Eiben, Robert M., 126–132
Electric stimulation, S53–S54
Electroencephalogram, 41–43, 309–312, 445–449, 485
Electromyography, 21, 22, 116–120
Encephalitis, 232
Encephalopathy, 193–196, 234, 347
Endplate acetylcholinesterase deficiency, 345–346
Energy cost, of mobility, S68
Entorhinal region, 267–268
Environmental poisons, 172
Enzyme deficiency, 302, 307
Ependymoma, 229–230
Epidural lipomatosis, 236–240
Epilepsy, 41–43, 157–158, 201–204, 211–214, 259, 270–271, 321–330, 350, 422–424, 445–449, 500–501
Epstein–Barr virus, 232
Esophageal reflux, S17
Exertional myoglobinuria, 152–153
Expert witness, 171

Extrapyramidal cerebral palsy, S8, S9–S10, S19

Fabry's disease, 302, 307
Familial convulsions, 211–214
Familial desminopathy, 149
Familial dystonia, 185–187
Familial ventricular dysrhythmia, 151–152
Farber's lipogranulomatosis, 302, 307
Fatigue, 154, 430–432, S17
FDG–PET, 451–456
Felbamate, 170
Fetal hydrocephaly, 189–192
Fiber myopathy, 71–73, 228
Fina, Saint, 258
Fine motor function measures, S65
Fluoxetine, 226, S15
Fluphenazine, S15, S16
Food, 172
Force, in movement disorders, S67
Free radical scavengers, 365
Fumarase deficiency, 252–254
Functional limitations, S62–S68

GABA, 355–356, 359–360, S19–S20, S30
Gabapentin, 470–474
Ganglia, 112–115, 356–357, S8–S9, S18–S19, S48–S49
Gastroesophageal reflux, 98–100
Gaucher's disease, 302, 307
Germinal cells, 313–320
Global cerebral dysplasia, 313–320
Glucose, 451–456
Glutamate, S19
Glutaric aciduria, 167–169, 414–416
Glycogenesis, 148–149
Glycoproteinoses, 302–303, 307
Gross Motor Function Measure, S64–S65
Guillain–Barré syndrome, 1–2, 4–11, 407–410
Gum, 210

Haloperidol, S15, S16
Head circumference, 389–392
Head injury, 283–289
Heart disease, 49–52
Hematomas, 231
Hemidystonia, 167–169
Hemiplegia, S7–S8
Hemorrhage, 230
Hemorrhagic telangiectasia, 231
Hereditary peripheral neuropathies, 133–144, 150–151
Hereditary spastic paraparesis, 54–57, 150
Hippocampus, 263–273
Home physical therapy, S55
Homocystinuria, 70–71, 235–236
Hormones, 384, 385, 387
Hunter's disease, 303, 307
Hydrocephalus, 370–372
Hydrocephaly, 189–192, 336–340
Hydroxyglutaric acidemia, 373–377
Hyperparathyroidism, 152
Hyperplasia, 313–320, 400–403, 489
Hypertensive encephalopathy, 193–196, 347
Hypertrophy, 210
Hypnotics, 363
Hypomyelination, 153
Hypoplasia, 241–243
Hypothalamic-pituitary-adrenal axis, 384, 385, 386–387
Hypothermia, 49–52
Hypothyroidism, 486–487
Hypotonia, 252–254
Hypoxic-ischemic injury, S10

Idiopathic mental retardation, 197–199
Imipramine, 226, S15
Immunodeficiency, 159–161, 336–340
Immunomodulation, 364–365
Impairment, motor, S62–S68
Impairment indices, 232
Infantile autism, 84–91
Infantile progressive striatothalamic degeneration, 230
Infantile spasms, 31–34, 35–40, 44–48, 170, 188, 350, 383–387
Infants, 49–52, 70–71, 98–100, 153–154, 172, 181–184, 215–219, 230
Inflammatory demyelinating polyradiculoneuropathy, 147, 149
Inflammatory myopathy, 232
Intracerebral hemorrhage, 230
Intracranial mass, 336–340
Intraoral trauma, 419–422
Intrathecal baclofen, S29–S34
Involuntary movements, S66
Ischemia, 181–184

Jaw muscle, 154

Klinefelter syndrome, 232
Krabbe's disease, 302, 307

Lambert-Eaton syndrome, 152
Landau-Kleffner syndrome, 231, 347–349
Lateral sclerosis, 54–57, 152
Learning disorders, 41–43, 74, 220–227, 427–428, 486–487, 505–506
Leber's congenital amaurosis, 108–111
Lennox-Gastaut syndrome, 31–34, 229
Leptomeninges, 404–407, 410–413
Lesch-Nyhan syndrome, 476–478
Lesions, 230–231
Leukodystropathy, 439–444
Leukoencephalopathy, 439–444
Levodopa, S15, S16, S17
Limb-girdle weakness, 14–15
Limbic loop, 265–267
Line-of-migration abnormality, 157–158
Lipids, 276–281
Lipofuscinosis, 234, 302, 307
Lipogranulomatosis, 302, 307
Lipomatosis, 236–240
Lipoproteins, 276–281
Lissencephaly, 241–243
Lithium carbonate, 227
Liver disease, 417–419
Lobectomy, 445–449
Lorazepam, S15, S16
L-2-hydroxyglutaric acidemia, 373–377
Lysosomal glycogenesis, 148–149
Lysosomal storage diseases, 301–308

Macrocephaly, 414–416
Magnetic resonance angiography, 419–422
Magnetic resonance imaging, 113, 150, 157–158, 164–167, 236–240, 373–377, 445–449, 451–456, 497–499
Magnocellular nuclei, 272
Malaria, 257–258
McLean, William T., Jr, 425
Medulloblastoma, 53
Megalencephaly, 439–444
Melanoma, 410–413
Melatonin, 341–345
Meningoencephalitis, 159–161
Mental retardation, 197–199, 341–345
Merosin deficiency, 154, 291–295
Metabolic inhibitors, 366
Metabolic lesions, 230–231
Methocarbamol, S17
Methylphenidate, 227
Microgyria, 494–496
Middle cerebral artery, 494–496
Mini-Mental State Examination, 228
Mitochondrial dysfunction, 108–111
Monoamine oxidase inhibitors, 362
Monoamines, 361
Mononeuropathy, 116–120
Motion analysis, S66
Motor dyspraxia, 484
Motor skills, 232, 260–261, S65
Movement disorders, 353–366, S1–S3, S5–S11, S13–S20, S29–S34, S51–S58, S61–S68
MRI, 113, 150, 157–158, 164–167, 236–240, 373–377, 445–449, 451–456, 497–499
Mucopolysaccharidoses, 303, 307
Multiple sulfatase, 302, 307
Mumps meningoencephalitis, 159–161
Muscle, 21–22, 154, 210, 246–247, 430–432, 507–508, S29
Muscular dystrophy, 13–18, 150, 154, 291–295
Myalgias, 16–17, 21–23, 230
Myasthenia gravis, 152, 458–460
Mycoplasma, 229
Myelin protein gene, 133–144
Myelitis, 229
Myelomeningocele, 370–372
Myoclonus, 360, S14
Myoglobinuria, 152–153
Myopathy, 15–16, 71–73, 147–148, 151, 228, 232
Myophosphorylase deficiency, 148
Myotonic dystrophy, 430–432
Myotonic myopathy, 147–148
Myotubular myopathy, 151

Naltrexone, 362
Necrosis, 185–187

Neocortex, 265–267
Neonatal adrenoleukodystrophy, 231
Neonatal axonal polyneuropathy, 153–154
Neonatal cerebral arterial thrombosis, 250–251
Neonatal hereditary hemorrhagic telangiectasia, 231
Neonatal seizures, 378–381
Neonate, 255–256
Nerve growth factor, 296–300, 384–385, 386, 387
Nerve pathologist, 143–144
Neuroanatomic pathways, 356–357
Neurocutaneous melanosis, 410–413
Neuroectodermal tumor, 404–407
Neuroimaging, 260
Neurological Disability Assessment and Index, 173–180
Neurological rehabilitation, 350–351
Neurological Severity Score, 462–468, 469
Neuromuscular blockade, 345–346, 364, S23–S28
Neuromyelitis optica, 164–167
Neuronal ceroid lipofuscinosis, 234, 302, 307
Neuronal degeneration, 417–419
Neuropathy, 133–144, 147, 150–151, 153–154, 400–403, 489
Neurotransmitters, 355–356, 358–359, 384, 386, S18–S19
Newborn, 49–52, 70–71, 98–100, 153–154, 172
Niemann-Pick disease, 302, 307
Nimodipine, 500–501
Nitrazepam, 31–34
Nonverbal learning disabilities, 427–428
Nortriptyline, 226

Oculocephalic reflex, 255–256
Open-heart surgery, 49–52
Opiate receptors, 362–363
Opiates, 363
Optic atrophy, 153
Oral contraceptives, 364
Orthoses, S53
Oxidative stress, 433–438

Pallidum, S45–S46
Panencephalitis, 173–180, 233
Papilledema, 229–230
Paralysis, 54–57, 150
Paraparesis, 54–57, 150, 229
Parkinsonian manifestations, 235–236
Paroxetine, 226, S15
Partial seizures, 492–494
Patterning, S54–S55
Pemoline, 227
Penry, James Kiffin, 509
Pentoxifylline, 501–503
Perceptual dysfunction, 484–485
Pergolide, S15
Perineurial hyperplasia, 400–403, 489
Peripheral neuromuscular blockade, 364
Peripheral neuropathies, 133–144, 150–151
Periventricular germinal cells, 313–320
Persistent vegetative state, 255–256
Pervasive development disorder, 427–428
PET, 44–48, 167–169, 230–231, 451–456
Pharmacotherapy, S13–S20
Phenobarbital, S15, S16
Phenol, S25
Phenytoin, 490–491
Physical therapy, 350–351, S51–S58
Pimozide, S15, S16
Piracetam, 363, S16
Plantar response, 230
PMP22 gene, 133–144
Poisons, 172
Polyglucosan bodies, 58–62
Polyneuropathy, 147, 149, 153–154
Pompe's disease, 302, 307
Pontocerebellar hypoplasia, 241–243
Porphyria, 229
Positron emission tomography, 44–48, 167–169, 230–231, 451–456
Posture, S67
Prader-Willi syndrome, 121–124
Presubicular circuit, 271
Primary disorder of vigilance, 220–227
Primary lateral sclerosis, 54–57
Primary primitive neuroectodermal tumor of leptomeninges, 404–407
Primary spinal leptomeningeal melanoma, 410–413
Primidone, S15, S16
Primitive neuroectodermal tumor of leptomeninges, 404–407
Progressive neuronal degeneration, 417–419
Progressive striatothalamic degeneration, 230
Propranolol, S15
Protein C, 250–251
Protein gene, 133–144
Protriptyline, 226
Proximal myotonic myopathy, 147–148
Pseudohypertrophy, 151
Psychostimulants, 363
Ptosis, 228–229
Pyridoxal phosphate, 35–40
Pyridoxine-dependent epilepsy, 422–424

Quadriceps myopathy, 15
Quadriplegia, S7

Range of motion, S67–S68
Receptors, 355–356, 362–363
Reflex, 205–209, 255–256
Reflux, 98–100, S17
Rehabilitation, 350–351, S51–S58
Respiratory chain dysfunction, 417–419
Respiratory sinus arrhythmia, 121–124
Retardation, 197–199, 341–345
Rett syndrome, 232, 296–300
Rhizotomy, S36–S41
Rigidity, S47

Sagittal sinus thrombosis, 70–71
Saint Fina, 258
Salla disease, 303, 307
Sarcoid myopathy, 151
Saudi Arabia, 232–233, 234
Schindler disease, 302, 307
School performance, 309–312
School physical therapy, S56–S57
Sclerosing panencephalitis, 173–180, 233
Sclerosis, 54–57, 152
Seating systems, S53
Sedatives, 363
Segawa's disease, 353
Seizures, 98–100, 350, 378–381, 470–474, 492–494
Selegiline, S15
Self-mutilation, 476–478
Sensory rhizotomy, S36–S41
Serotonergic drugs, S17
Serotonin, 362, S20
Sertraline HCl, 226
Serum creatine kinase, 21, 22
Sex hormones, 384, 385, 387
Shunt, 370–372
Sickle cell encephalopathy, 234
SIDS, 101–106, 181–184, 433–438
Sign language, 347–349
Single enzyme deficiency, 302, 307
Sinus arrhythmia, 121–124
Sinus thrombosis, 70–71
Skeletal muscle, 430–432
Skin biopsy, 301–308
Sleep, 341–345, 507
Spasms, 31–40, 44–48, 170, 188, 350, 383–387
Spasticity, 231–232, S1–S3, S5–S7, S14, S31, S36–S41, S53, S66–S67
Spastic paralysis, 54–57, 150
Spastic paraparesis, 54–57, 150, 229
Spastic quadriplegia, S7
Speed, in movement disorders, S66
Sphingolipidoses, 302, 307
Spinal cord, 78, 229–230
Spinal leptomeningeal melanoma, 410–413
Spinal muscular atrophy, 154, 246–247
Stereotaxis, S43–S49
Steroids, 229
Stimulation, electrical, S53–S54
Storage diseases, 301–308
Strength, S52–S53
Stress, 433–438, S17
Striatal necrosis, 185–187
Striatothalamic degeneration, 230
Stroke, 276–281, 419–422
Subacute sclerosing panencephalitis, 173–180, 233
Subarachnoid spaces, 197–199, 414–416
Subdural hematomas, 231
Sudden infant death syndrome, 101–106, 181–184, 433–438

Sulfatide activator deficiency, 302
Surgery, heart, 49–52

Task-dependent attention disorders, 220–227
Tay-Sachs disease, 234
Telangiectasia, 231
Temporalis muscles, 210
Temporal lobectomy, 445–449
Tetrabenazine, S15, S16
Thalamus, 271, S45–S46
Thioridazine, 227, S15
Thrombosis, 70–71, 248–249, 250–251
Torsion dystonia, 343–345
Tourette syndrome, 93–96, 353
Tranquilizers, S17
Transentorhinal region, 267–268
Transplantation, 159–161
Trauma, 419–422
Tremor, 360, S47–S48
Tricyclic antidepressants, 362
Trihexyphenidyl, S15, S16
Tropical spastic paraparesis, 229
Tuberomamillary nucleus, 272
Tumor, 404–407, 410–413
Type I fiber myopathy, 228

Ulnar mononeuropathy, 116–120

Valproate, 227, 321–330, S15, S16
Valproic acid, 41–43, 505–506
Vegetative state, 255–256
Venous thrombosis, 248–249
Ventricular dysrhythmia, 151–152
Ventriculomegaly, 189–192
Ventriculoperitoneal shunt, 370–372
Vertebral artery, 181–184
Vigabatrin, 188
Vineland Adaptive Behavior Scales, 283–289
Vitamin K, 244–245
Vitamins, 365–366
Volvular epilepsy, 157–158

Wechsler Intelligence Scale for Children, 41–43
Weight, 215–219
West syndrome, 350
Williams syndrome, 63–65
Wolman's disease, 302, 307

PEDIATRIC NEUROLOGIST

Immediate opening for a second child neurologist at this 188 bed, private teaching children's hospital that serves as tertiary care referral center for South Texas. Driscoll Children's Hospital is located in a beautiful coastal city of 250,000. The successful candidate must be BC/BE in child neurology and in pediatrics. Responsibilities include the provision of clinical care, teaching of pediatric and family practice residents and medical students, and limited administrative responsibilities. Faculty appointment at affiliated university medical center is expected and opportunities exist for research. Competitive salary and benefits package. Additional training or experience in epilepsy, neuromuscular disease, behavioral/developmental neurology, or neurorehabilitation is desirable and fluency in Spanish as well as English is a plus.

Please send CV and three letters of reference to Gary B. Bobele, MD, Department of Medical Education, Driscoll Children's Hospital, PO Box 6530, 3533 S. Alameda, Corpus Christi, TX 78466-6530.

Parke-Davis BECTS Study

Parke-Davis is seeking patients with Benign Childhood Epilepsy with Centrotemporal Spikes (BECTS), also known as Rolandic Seizures, to participate in a research study. The purpose of this research is to determine the effectiveness of the study drug in monotherapy in a pediatric population.

There are approximately 45 centers throughout the US and Canada participating in this research. To qualify for the study, a child must have diagnosed BECTS, 1–10 seizures within the past 6 months, be 4–13 years old and on no antiepileptic (AED) medication or only one AED. This study will provide free of charge all study medication, doctor's visits, study tests, and expenses for travel for visits related to and during the course of the study. Three behavioral/cognitive testing sessions will be administered to assess the child's development and progress.

Physicians conducting the study will be responsible for the care and progress of the child relating only to the clinical study. Patients should continue their other health and wellness care with their regular family care physicians.

For more information call (800) 797-0822.

Pediatric Epilepsy and EEG Fellowship

The Blue Bird Clinic for Pediatric Neurology is offering a 2-year fellowship (the E.L. "Pete" Wehner Fellowship in Pediatric Epilepsy) beginning July 1, 1997, to an individual who is board-eligible in pediatric neurology. The Program is affiliated with the Division of Pediatric Neurology of Baylor College of Medicine and Texas Children's Hospital and provides opportunities to learn epileptology and pediatric electroencephalography. The Children's Comprehensive Epilepsy Center, located in the Blue Bird Clinic and Texas Children's Hospital, provides a full range of medical, neurosurgical, psychological, social, and rehabilitative services to children with intractable seizures. The fellow would participate in the intensive evaluation of children being considered for epilepsy surgery and in the investigational anticonvulsant drug programs at the Blue Bird Clinic. Send letter of inquiry to Barry R. Tharp, MD, The Blue Bird Clinic for Pediatric Neurology, The Methodist Hospital, 6501 Fannin, NB-100, Houston, TX 77030, USA.